Core Wealth Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Core Wealth Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$241K	Buy	+800	New	+$241K	0.1%	159

Other funds holding ALNY

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

MIF

Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

SSA

Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return

FISPB

Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM

OIAM

OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

Core Wealth Partners's ALNY Position: Q2 2026 in Review

Core Wealth Partners opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 800 shares worth $241K. The stake represents 0.1% of the portfolio and ranks #159 among its holdings.

149 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Core Wealth Partners held 800 shares of Alnylam Pharmaceuticals worth $241K as of Q2 2026.
Alnylam Pharmaceuticals was a new Core Wealth Partners position in Q2 2026.
Alnylam Pharmaceuticals made up 0.1% of Core Wealth Partners's portfolio in Q2 2026, its #159 holding.
149 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Core Wealth Partners's 13F filing for Q2 2026, filed 17 Jul 2026.